| Literature DB >> 28119557 |
Siddharth Sinha1, Sukriti Goyal2, Pallavi Somvanshi1, Abhinav Grover3.
Abstract
Spinocerebellar ataxia (SCA-2) type-2 is a rare neurological disorder among the nine polyglutamine disorders, mainly caused by polyQ (CAG) trinucleotide repeats expansion within gene coding ataxin-2 protein. The expanded trinucleotide repeats within the ataxin-2 protein sequesters transcriptional cofactors i.e., CREB-binding protein (CBP), Ataxin-2 binding protein 1 (A2BP1) leading to a state of hypo-acetylation and transcriptional repression. Histone de-acetylases inhibitors (HDACi) have been reported to restore transcriptional balance through inhibition of class IIa HDAC's, that leads to an increased acetylation and transcription as demonstrated through in-vivo studies on mouse models of Huntington's. In this study, 61 di-aryl cyclo-propanehydroxamic acid derivatives were used for developing three dimensional (3D) QSAR and pharmacophore models. These models were then employed for screening and selection of anti-ataxia compounds. The chosen QSAR model was observed to be statistically robust with correlation coefficient (r2) value of 0.6774, cross-validated correlation coefficient (q2) of 0.6157 and co-relation coefficient for external test set (pred_r2) of 0.7570. A high F-test value of 77.7093 signified the robustness of the model. Two potential drug leads ZINC 00608101 (SEI) and ZINC 00329110 (ACI) were selected after a coalesce procedure of pharmacophore based screening using the pharmacophore model ADDRR.20 and structural analysis using molecular docking and dynamics simulations. The pharmacophore and the 3D-QSAR model generated were further validated for their screening and prediction ability using the enrichment factor (EF), goodness of hit (GH), and receiver operating characteristics (ROC) curve analysis. The compounds SEI and ACI exhibited a docking score of -10.097 and -9.182 kcal/mol, respectively. An evaluation of binding conformation of ligand-bound protein complexes was performed with MD simulations for a time period of 30 ns along with free energy binding calculations using the g_mmpbsa technique. Prediction of inhibitory activities of the two lead compounds SEI (7.53) and ACI (6.84) using the 3D-QSAR model reaffirmed their inhibitory characteristics as potential anti-ataxia compounds.Entities:
Keywords: 3D-QSAR; HDAC inhibitors; ROC curve; enrichment factor (EF); goodness of hit (GH); pharmacophore modeling; polyglutamine disorder; spinocerebellar ataxia type-2
Year: 2017 PMID: 28119557 PMCID: PMC5223442 DOI: 10.3389/fnins.2016.00606
Source DB: PubMed Journal: Front Neurosci ISSN: 1662-453X Impact factor: 4.677
Unicolumn statistics for the training and test set.
| Training | 6.9721 | 8.0000 | 5.0400 | 0.6669 | 271.9100 |
| Test | 6.7920 | 7.5200 | 6.2600 | 0.4850 | 33.9600 |
Statistical parameters for the 3D-QSAR model.
| pIC50 | 7.15928 | 3.21294 | 0.27393 | 0.01881 | 0.00000 | 0.00100 | 2.94453 | 0.27293 | 0.01000 |
Figure 3Contribution plot for the selected molecular properties in 3D-QSAR model.
Figure 4Depiction of aligned congeneric set of molecules and 3D descriptors marked in the cubic grid.
Different pharmacophore hypothesis generated for virtual screening.
| 1 | DDHHR.2 | 3.789 | 1.220 | 1.564 | 25 |
| 2 | DDHHR.37 | 3.584 | 1.162 | 1.595 | 25 |
| 3 | ADDRR.5 | 3.712 | 1.161 | 1.598 | 25 |
| 4 | ADDRR.8 | 3.789 | 1.220 | 1.564 | 25 |
| 5 | |||||
| 6 | ADDRR.53 | 3.832 | 1.242 | 1.594 | 25 |
| 7 | ADDRR.55 | 3.695 | 1.175 | 1.593 | 25 |
| 8 | ADDRR.67 | 3.832 | 1.242 | 1.594 | 25 |
| 9 | ADDRR.70 | 3.695 | 1.175 | 1.593 | 25 |
| 10 | DHHRR.15 | 3.846 | 1.230 | 1.597 | 25 |
| 11 | DHHRR.19 | 3.712 | 1.161 | 1.598 | 25 |
| 12 | ADHRR.42 | 3.675 | 1.195 | 1.594 | 25 |
| 13 | ADHRR.51 | 3.813 | 1.263 | 1.596 | 25 |
Figure 5Hydroxamic based HDAC inhibitors marked with pharmacophore features of ADDRR.20. (A) Alignment of molecules along with pharmacophore features. (B) Intersite distance between pharmacophore sites.
Statistical parameters for the calculation of Goodness of hit score (GH) and Enrichment Factor (EF).
| 1 | Total molecules in database (D) | 82254 |
| 2 | Total Number of Actives (A) | 4930 |
| 3 | Total hits (Ht) | 5689 |
| 4 | Active hits (Ha) | 4437 |
| 5 | % Yield of Actives [(Ha/Ht) × 100] | 78.01 |
| 6 | % Ratio of Actives [(Ha/A) × 100] | 90.05 |
| 7 | Enrichment Factor (E) [(Ha × D) / (Ht × A)] | 13.012 |
| 8 | False negatives [A − Ha] | 493 |
| 9 | False positives [Ht − Ha] | 1252 |
| 10 | Goodness of hit score (GH) | 0.796 |
[(Ha/4HtA) (3A + Ht) × (1 − ((Ht − Ha) / (D − A)))]; GH score of >0.7 indicates a statistically good model.
ROC curve cut-off values along with their respective true positive rate and false positive rate.
| 1 | 6 | 0.66 | 0.89 | 0.11 |
| 2 | 7 | 0.89 | 0.71 | 0.29 |
| 3 | 8 | 0.97 | 0.50 | 0.50 |
Figure 1(A) Fitness plot for the training and test set. (B) Receiver Operating Characteristic (ROC) curve for 3D-QSAR model.
Figure 6Interactions between HDAC4 protein and selected compounds (A) ACI (B) SEI.
Predicted activity of the top scoring compound using the selected pharmacophore hypothesis.
| Zinc 00608101 | − | ||||||
| Zinc 19702930 | −10.02283 | 1.251246 | 0.738099 | 0.415301 | 1.084544 | 7.22 | Pro676, Arg681 |
| Zinc 20464210 | −10.07625 | 1.203255 | 0.673085 | 0.42716 | 1.115548 | 6.94 | Asp934, His976 |
| Zinc 00329110 | − | ||||||
| Zinc 00897385 | −9.182680 | 1.401166 | 0.816804 | 0.335443 | 1.102823 | 6.82 | No interaction |
| Zinc 20465875 | −9.769430 | 1.591722 | 0.669213 | 0.41623 | 0.718525 | 6.81 | His131-Asp166 |
| Zinc 00518218 | −9.769608 | 1.081293 | 0.507579 | 0.431319 | 1.298446 | 6.08 | No interaction |
The bold values represent the selected entity.
Figure 7(A) Chemical structures of (a) SEI (b) ACI. (B) Interactions pattern between the HDAC4 protein for the screen molecules (b) ZINC 00897385 and (a) ZINC 005182189, respectively.
Figure 8(A) RMSD graph for the selected compounds for SEI and ACI for a time period of 20 ns. (B) Potential energy graph for selected compounds SEI and ACI for a time period of 30 ns.
The binding free energies for SEI and ACI complex.
| 1 | SEI | −2229.795 | 560.762 | −14.522 | −1683.555 |
| 2 | ACI | −2173.816 | 595.772 | −13.857 | −1591.901 |
Figure 2Radar plots demonstrating actual and predicted value for (A) Training (B) Test set.